Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases

Fate Therapeutics, Inc. (NASDAQ:FATE) announced today that it will present groundbreaking clinical data from its Phase 1 trial of FT819, an off-the-shelf, iPSC-derived CAR T-cell therapy, at the upcoming EULAR 2025 Congress in Barcelona. FT819 targets CD19 and is being evaluated in patients with moderate-to-severe systemic lupus erythematosus (SLE) without the use of fludarabine conditioning, a significant shift from traditional CAR T-cell approaches.

The oral presentation, scheduled for June 11, will highlight FT819’s safety and efficacy in lupus patients treated with either a fludarabine-free regimen or maintenance therapy without conditioning. This approach could eliminate the need for toxic chemotherapy, potentially enabling safer, more accessible outpatient treatment for autoimmune diseases.

Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases

A biotechnologist in a lab overlooking a microscope, examining a sample of substances to test for therapeutic properties.

Fate Therapeutics, Inc. (NASDAQ:FATE) will also showcase preclinical advances in its iPSC-derived CAR T and CAR-NK cell platforms, including Sword and Shield technology and multi-antigen targeting, aimed at broadening autoimmune therapy applications. The company’s proprietary iPSC platform allows for scalable, off-the-shelf cell therapies, positioning Fate Therapeutics, Inc. (NASDAQ:FATE) as a leader in next-generation immunotherapies for autoimmune conditions.

While we acknowledge the potential of AMZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than AMZN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.